~~30613257~~

10/539,708

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEAL1624

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS 4	OCT 30	CHEMLIST enhanced with new search and display field
NEWS 5	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS 6	NOV 10	CA/CAplus F-Term thesaurus enhanced
NEWS 7	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS 8	NOV 20	CA/CAplus to MARPAT accession number crossover limit increased to 50,000
NEWS 9	DEC 01	CAS REGISTRY updated with new ambiguity codes
NEWS 10	DEC 11	CAS REGISTRY chemical nomenclature enhanced
NEWS 11	DEC 14	WPIDS/WPINDEX/WPIX manual codes updated
NEWS 12	DEC 14	GBFULL and FRFULL enhanced with IPC 8 features and functionality
NEWS 13	DEC 18	CA/CAplus pre-1967 chemical substance index entries enhanced with preparation role
NEWS 14	DEC 18	CA/CAplus patent kind codes updated
NEWS 15	DEC 18	MARPAT to CA/CAplus accession number crossover limit increased to 50,000
NEWS 16	DEC 18	MEDLINE updated in preparation for 2007 reload
NEWS 17	DEC 27	CA/CAplus enhanced with more pre-1907 records
NEWS 18	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS 19	JAN 16	CA/CAplus Company Name Thesaurus enhanced and reloaded
NEWS 20	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS 21	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS 22	JAN 22	CA/CAplus updated with revised CAS roles
NEWS 23	JAN 22	CA/CAplus enhanced with patent applications from India
NEWS 24	JAN 29	PHAR reloaded with new search and display fields
NEWS 25	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS 26	FEB 13	CASREACT coverage to be extended
NEWS 27	Feb 15	PATDPASPC enhanced with Drug Approval numbers
NEWS 28	Feb 15	RUSSIAPAT enhanced with pre-1994 records
NEWS 29	Feb 23	KOREAPAT enhanced with IPC 8 features and functionality
NEWS 30	Feb 26	MEDLINE reloaded with enhancements
NEWS 31	Feb 26	EMBASE enhanced with Clinical Trial Number field
NEWS 32	Feb 26	TOXCENTER enhanced with reloaded MEDLINE
NEWS 33	Feb 26	IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS 34	Feb 26	CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases

Erich Leeser

50613257

```
 NEWS EXPRESS  NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8
 NEWS X25      X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:05:08 ON 13 MAR 2007

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'REGISTRY' ENTERED AT 15:05:40 ON 13 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   12 MAR 2007  HIGHEST RN 926069-79-6
DICTIONARY FILE UPDATES:  12 MAR 2007  HIGHEST RN 926069-79-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10539708new.str

L1      STRUCTURE UPLOADED

=> s l1
SAMPLE SEARCH INITIATED 15:06:02 FILE 'REGISTRY'
```

Erich Leeser

50613257

SAMPLE SCREEN SEARCH COMPLETED - 3 TO ITERATE

100.0% PROCESSED 3 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 3 TO 163
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l2 full
FULL SEARCH INITIATED 15:06:15 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 42 TO ITERATE

100.0% PROCESSED 42 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.01

L3 2 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 172.10 172.31

FILE 'CAPLUS' ENTERED AT 15:06:20 ON 13 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 13 Mar 2007 VOL 146 ISS 12
FILE LAST UPDATED: 11 Mar 2007 (20070311/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3 full
L4 1 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:525895 CAPLUS
DOCUMENT NUMBER: 141:89095
TITLE: Preparation of 3-substituted 3,4-dihydrothieno[2,3-

Erich Leeser

50613257

d]pyrimidin-4-ones as central nervous system agents

PATENT ASSIGNEE(S): Abbott GmbH & Co. Kg, Germany
SOURCE: Ger. Offen., 32 pp.
CODEN: GWXXBX

DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10259382	A1	20040701	DE 2002-10259382	20021218
WO 2004055024	A1	20040701	WO 2003-EP14423	20031217
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003300529	A1	20040709	AU 2003-300529	20031217
EP 1572698	A1	20050914	EP 2003-813137	20031217
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2006142317	A1	20060629	US 2005-539708	20051230

PRIORITY APPLN. INFO.: DE 2002-10259382 A 20021218
WO 2003-EP14423 W 20031217

OTHER SOURCE(S): MARPAT 141:89095
GI



I



II

Erich Leeser

50613257

AB Title compds. [I; A = O, S, SO, NR5, CH2; R5 = N, alkyl, aryl, aralkyl, acyl, alkoxycarbonyl; R4 = H, Me; m, n = 0, 1; R1 = alkylene; R2 = 1,4-piperazinylene, 1,4-piperidinylene, 1,3-pyrrolidinylene, 1,4-homopiperazinylene, etc.; R3 = (substituted) (aryl- or heteroaryl-condensed) 5-membered heteroaryl], were prepared Thus, title compound (II) bound to 5-HT1A and 5-HT1B receptors with Ki = 0.5 nM and 0.6 nM, resp.

IT 713508-93-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of dihydrothienopyrimidinones as central nervous system agents)

RN 713508-93-1 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[2-[4-(5-methyl-1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

=>
=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	18.43	190.74

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.78	-0.78

FILE 'REGISTRY' ENTERED AT 15:23:13 ON 13 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 12 MAR 2007 HIGHEST RN 926069-79-6
DICTIONARY FILE UPDATES: 12 MAR 2007 HIGHEST RN 926069-79-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Erich Leeser

50613257

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\cory.str

L5 STRUCTURE UPLOADED

=> s l5
SAMPLE SEARCH INITIATED 15:23:40 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 1193 TO ITERATE

100.0% PROCESSED 1193 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 21788 TO 25932
PROJECTED ANSWERS: 0 TO 0

L6 0 SEA SSS SAM L5

=> s l6 full
FULL SEARCH INITIATED 15:23:48 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 23652 TO ITERATE

100.0% PROCESSED 23652 ITERATIONS 45 ANSWERS
SEARCH TIME: 00.00.01

L7 45 SEA SSS FUL L5

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	172.10	362.84

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-0.78

FILE 'CAPLUS' ENTERED AT 15:23:54 ON 13 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Erich Leeser

50613257

databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 13 Mar 2007 VOL 146 ISS 12
FILE LAST UPDATED: 11 Mar 2007 (20070311/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l7 full
L8 2 L7

=> d ibib abs hitstr tot

L8 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:525895 CAPLUS
DOCUMENT NUMBER: 141:89095
TITLE: Preparation of 3-substituted 3,4-dihydrothieno[2,3-d]pyrimidin-4-ones as central nervous system agents
PATENT ASSIGNEE(S): Abbott GmbH & Co. Kg, Germany
SOURCE: Ger. Offen., 32 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
DE 10259382	A1	20040701	DE 2002-10259382		20021218
WO 2004055024	A1	20040701	WO 2003-EP14423		20031217
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2003300529	A1	20040709	AU 2003-300529		20031217
EP 1572698	A1	20050914	EP 2003-813137		20031217
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
US 2006142317	A1	20060629	US 2005-539708		20051230
PRIORITY APPLN. INFO.:			DE 2002-10259382	A	20021218
			WO 2003-EP14423	W	20031217

OTHER SOURCE(S): MARPAT 141:89095
GI

Erich Leeser

50613257



I



II

AB Title compds. [I; A = O, S, SO, NR5, CH2; R5 = N, alkyl, aryl, aralkyl, acyl, alkoxycarbonyl; R4 = H, Me; m, n = 0, 1; R1 = alkylene; R2 = 1,4-piperazinylene, 1,4-piperidinylene, 1,3-pyrrolidinylene, 1,4-homopiperazinylene, etc.; R3 = (substituted) (aryl- or heteroaryl-condensed) 5-membered heteroaryl], were prepared Thus, title compound (II) bound to 5-HT1A and 5-HT1B receptors with Ki = 0.5 nM and 0.6 nM, resp.

IT 713508-88-4P 713508-89-5P 713508-90-8P
713508-91-9P 713508-92-0P 713508-93-1P
713508-94-2P 713508-95-3P 713508-96-4P
713508-97-5P 713508-98-6P 713508-99-7P
713509-00-3P 713509-01-4P 713509-02-5P
713509-03-6P 713509-04-7P 713509-06-9P
713509-08-1P 713509-09-2P 713509-10-5P
713509-11-6P 713509-12-7P 713509-13-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of dihydrothienopyrimidinones as central nervous system agents)

RN 713508-88-4 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl- (9CI) (CA INDEX NAME)



Erich Leeser

50613257

RN 713508-89-5 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(4-chloro-1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl- (9CI) (CA INDEX NAME)



RN 713508-90-8 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[2-[4-[5-(trifluoromethyl)-2-benzothiazolyl]-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)



RN 713508-91-9 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(5-chloro-2-benzothiazolyl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl- (9CI) (CA INDEX NAME)



RN 713508-92-0 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(1H-benzimidazol-2-yl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl- (9CI) (CA INDEX NAME)

Erich Leeser



RN 713508-93-1 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[2-[4-(5-methyl-1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 713508-94-2 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(2-benzoxazolyl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl- (9CI) (CA INDEX NAME)



RN 713508-95-3 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(2-benzothiazolyl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl- (9CI) (CA INDEX NAME)



RN 713508-96-4 CAPLUS

Erich Leeser

50613257

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 713508-97-5 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(1H-indazol-3-yl)-1-piperazinyl]ethyl]-7-methyl- (9CI) (CA INDEX NAME)



RN 713508-98-6 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[2-[4-(7-methyl-1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 713508-99-7 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(5-methoxy-1,2-benzisoxazol-3-yl)-1-piperazinyl]ethyl]-7-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Erich Leeser

50613257



● HCl

RN 713509-00-3 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(5-methoxy-1-methyl-1H-indol-3-yl)-1-piperidinyl]ethyl]-7-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 713509-01-4 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[2-[4-(5-methyl-3-benzofuranyl)-1-piperidinyl]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 713509-02-5 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(5-chloro-3-benzofuranyl)-1-piperidinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

50613257



● HCl

RN 713509-03-6 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-3-[2-[4-(1H-indol-3-yl)-1-piperidinyl]ethyl]-7-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 713509-04-7 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[3,6-dihydro-4-(1H-indol-3-yl)-1(2H)-pyridinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl- (9CI) (CA INDEX NAME)



RN 713509-06-9 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[3,6-dihydro-4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-1(2H)-pyridinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl-, monoacetate (9CI) (CA INDEX NAME)

CM 1

CRN 713509-05-8
CMF C24 H26 N6 O S

Erich Leeser

50613257 ··



CM 2

CRN 64-19-7
CMF C2 H4 O2



RN 713509-08-1 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[2-[4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-1-piperidinyl]ethyl]-, monoacetate (9CI) (CA INDEX NAME)

CM 1

CRN 713509-07-0
CMF C24 H28 N6 O S



CM 2

CRN 64-19-7
CMF C2 H4 O2



RN 713509-09-2 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-[5-(4-chlorophenyl)-1H-pyrazol-3-yl]-1-piperidinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Erich Leeser

50613257



● HCl

RN 713509-10-5 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[2-[4-[5-(2-thienyl)-1H-pyrazol-3-yl]-1-piperidinyl]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 713509-11-6 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(1H-benzotriazol-1-yl)-1-piperidinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Erich Leeser



● 2 HCl

RN 713509-12-7 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(1H-benzimidazol-1-yl)-1-piperidinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 713509-13-8 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-7-methyl-3-[2-[4-(1-phenyl-1H-tetrazol-5-yl)-1-piperazinyl]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

IT 713509-15-0 713509-16-1 713509-17-2
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of dihydrothienopyrimidinones as central nervous system agents)
RN 713509-15-0 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-(4-benzo[b]thien-3-

50613257

yl-3,6-dihydro-1(2H)-pyridinyl)ethyl]-5,6,7,8-tetrahydro-7-methyl- (9CI) (CA INDEX NAME)



RN 713509-16-1 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(2,1-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 713509-17-2 CAPLUS
CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[3,6-dihydro-4-(5-methoxy-1H-indol-3-yl)-1(2H)-pyridinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl- (9CI) (CA INDEX NAME)



L8 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:475944 CAPLUS
DOCUMENT NUMBER: 133:89541
TITLE: Preparation of thienopyrimidines for use in the prophylaxis and therapy of cerebral ischemia
INVENTOR(S): Steiner, Gerd; Schellhaas, Kurt; Lubisch, Wilfried; Holzenkamp, Uta; Starck, Dorothea; Knopp, Monika; Szabo, Laszlo; Emling, Franz; Garcia-Ladona, Francisco Javi; Hofmann, Hans-Peter; Unger, Liliane
PATENT ASSIGNEE(S): BASF A.-G., Germany
SOURCE: Ger. Offen., 26 pp.

Erich Leeser

50613257

CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19900545	A1	20000713	DE 1999-19900545	19990111
CA 2359253	A1	20000720	CA 1999-2359253	19991224
WO 2000041695	A1	20000720	WO 1999-EP10369	19991224
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1140096	A1	20011010	EP 1999-967980	19991224
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9916887	A	20011120	BR 1999-16887	19991224
TR 200102008	T2	20011221	TR 2001-200102008	19991224
HU 200201149	A2	20020729	HU 2002-1149	19991224
HU 200201149	A3	20030728		
JP 2002534465	T	20021015	JP 2000-593306	19991224
NZ 512767	A	20030530	NZ 1999-512767	19991224
ZA 2001005475	A	20021003	ZA 2001-5475	20010703
NO 2001003409	A	20010830	NO 2001-3409	20010710
BG 105689	A	20020228	BG 2001-105689	20010710
US 6387912	B1	20020514	US 2001-889162	20010711
PRIORITY APPLN. INFO.:			DE 1999-19900545 A	19990111
			WO 1999-EP10369 W	19991224

OTHER SOURCE(S): MARPAT 133:89541
GI



I



II

AB Thienopyrimidines I [A = O, NH; B = H, Me; D = Me, E = (un)substituted CONH2; DE = CH2CH2NR1CH2, CH2NR1CH2, CH2NR1CH2CH2; YZ = (CH2)mN, (CH2)mCH, CH2CH:C; m = 1-3; R1 = H, alkyl, Ac, Bz, (un)substituted phenylalkyl; R2 = (un)substituted Ph, pyridyl, pyrimidinyl, pyrazinyl] were prepared for use

Erich Leeser

in the treatment of cerebral ischemia and stroke (no data). Thus, the pyrido[4',3':4,5]thieno[2,3-d]pyrimidine II was prepared from the 2-ethoxymethylenamino analog and 1-(2-aminoethyl)-4-(2-methoxyphenyl)piperazine.

IT 281657-53-2P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thienopyrimidines for use in the prophylaxis and therapy of cerebral ischemia)

RN 281657-53-2 CAPLUS

CN Pyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one, 3-[2-[4-(2,3-dihydro-1H-inden-1-yl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-7-methyl-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl